Published Technical Disclosure Archive

Chimeric Animal Immune Response Management System

Publication ID: 24-11856927_0008_PTD
Published: October 26, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Chimeric Animal Immune Response Management System,” Published Technical Disclosure No. 24-11856927_0008_PTD, Published October 26, 2025, available at https://archive.pr1or.art/24-11856927_0008_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,856,927.

Background and Problem Solved

The original patent disclosed a method for treating and preventing immune response and inflammation in chimeric animals. However, the patent had limitations in terms of real-time monitoring, personalized treatment, and secure data management. The present invention addresses these limitations by synergistically combining distinct technologies to create a more powerful system.

Novelty and Inventive Step

The new claims introduce the integration of AI, IoT, blockchain, and genomics analysis, which is not obvious from the original patent. The inventive step lies in the synergistic combination of these technologies to create a more powerful system that addresses the limitations of the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the invention could include the use of different machine learning algorithms, integration with other IoT devices, or the incorporation of additional genomic analysis tools. Variations of the invention could also include the application of the system to other animal models or human subjects.

Potential Commercial Applications and Market

The integrated system has significant commercial potential in the fields of veterinary medicine, biotechnology, and pharmaceuticals. The system could be marketed to research institutions, veterinary hospitals, and pharmaceutical companies, providing a comprehensive solution for immune response and inflammation management in chimeric animals.

CPC Classifications

SectionClassGroup
A A01 A01K67/0271
A A61 A61K31/573
A A61 A61P37/06
A A01 A01K2217/05
A A01 A01K2217/075
A A01 A01K2227/105
A A01 A01K2267/035
C C12 C12N15/09

Field of Art

Veterinary biotechnology, immunology, and chimeric animal research, focusing on stem cell transplantation, immune response management, and advanced medical monitoring technologies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degrees in veterinary medicine, biotechnology, or biomedical engineering, possessing expertise in genetic engineering, immunological monitoring, and emerging medical technologies

Obviousness Rationale

A PHOSITA would recognize that integrating modern monitoring technologies with the source patent's chimeric animal treatment method represents a natural progression of existing medical research. The combination of machine learning, IoT sensors, and genomic analysis provides predictable and incremental improvements to the original inflammation management approach. These technological extensions directly address the source patent's core challenge of monitoring and managing immune responses in chimeric animals.

Obvious Combinations & Variations

Source Patent Element
Method for obtaining an adult individual from a chimeric animal fetus with no substantial inflammation
PTD Variation
Adding machine learning module to predict and monitor potential immune responses
Obviousness Reasoning
Predictable application of known machine learning techniques to existing medical monitoring, representing a routine optimization of the original method's diagnostic capabilities
Source Patent Element
Anti-inflammatory agent administration method
PTD Variation
Incorporating blockchain and IoT technologies for secure medical record management and real-time health tracking
Obviousness Reasoning
Known convergence of digital technologies with medical research, providing enhanced data management and monitoring capabilities through standard technological integration
Source Patent Element
Immunosuppressive treatment for chimeric animals
PTD Variation
Genomics analysis module for identifying genetic markers associated with immune response
Obviousness Reasoning
Logical extension of existing genetic research methodologies, applying standard genomic screening techniques to personalize treatment approaches
Source Patent Element
Monitoring immune response after birth
PTD Variation
Wearable IoT sensor system for continuous vital sign and biomarker tracking
Obviousness Reasoning
Predictable technological advancement using standard biomedical monitoring techniques, representing an incremental improvement in diagnostic capabilities
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11856927, the claimed variations represent obvious extensions of the original chimeric animal immune response management method. A person of ordinary skill in the art would find the integration of machine learning, IoT technologies, blockchain, and genomic analysis to be predictable and routine modifications that do not rise to the level of non-obvious invention, thus rendering subsequent claims obvious as a matter of law.

Original Patent Information

Patent NumberUS 11,856,927
TitleFinding and treatment of inflammation after birth in chimeric animal
Assignee(s)The University of Tokyo